Learning objectives
- Describe the effects and underlying mechanisms of bleomycin therapy
- Diagnose bleomycin pulmonary toxicity
- Manage patients who have received bleomycin therapy
Background
- Bleomycin is an antitumor antibiotic often used to treat germ cell tumors and Hodgkin’s disease
- Side-effect: Potential for subacute pulmonary damage that can progress to life-threatening pulmonary fibrosis
- Pulmonary toxicity occurs in 6–10% of patients
- Exposure to high-inspired concentration oxygen therapy, even for short periods, can cause rapidly progressive pulmonary toxicity in patients previously treated with bleomycin
- Lung injury typically develops within 6 months after the start of bleomycin treatment
- The potential for high-inspired fractions of oxygen to provoke pulmonary toxicity remains a life-long risk in these patients
- Symptoms of bleomycin-induced pulmonary toxicity include dry cough, breathlessness, pleuritic chest pain, and fever
Pathophysiology
- Bleomycin oxidatively damages DNA by binding to metal ions such as iron, resulting in reactive oxygen species formation
- Is inactivated by bleomycin hydrolase
- Low concentrations of bleomycin hydrolase in skin and lung tissues contribute to the sensitivity to bleomycin of these tissues
- Contributing factors to bleomycin pulmonary toxicity:
- Inflammatory cell infiltration into pulmonary endothelial cells
- Fibrotic changes with elevated collagen content
- Increased expression of fibrogenic mediators (TGF-beta, connective tissue growth factor, PDGF-C) in endothelial cells
- Decrease in thapsigargin-induced prostaglandin I2 and nitric oxide (vasodilators) in endothelial pneumocytes
Risk factors for pulmonary toxicity
- Advanced age
- Renal insufficiency
- Increased cumulative drug dose
- Severity of underlying malignancy
- FiO2 use
- Concomitant radiation therapy
- Other chemotherapeutic agents
- Smoking
Diagnosis
| Physical examination | Dyspnea |
| Pulmonary crackles | |
| Hypoxemia | |
| Radiology | Linear interstitial shadowing, which can look similar to Kerly B lines seen in pulmonary edema |
| Confluent airspace shadowing, which may be diagnosed as infection if the diagnosis of bleomycin lung injury is not considered |
|
| Pneumothorax and pneumomediastinum are recognized complications in severe bleomycin lung injury |
Management of patients who have received bleomycin
- Acoid oxygen therapy when possible
- Avoid clinical procedures (and leisure activities) involving a high FiO2
- If a patient is hypoxic, O2 therapy should be minimized to maintain O2 saturation of 88–92%
- High oxygen concentrations should be used with extreme caution for immediate life-saving indications only (to maintain O2 saturation of 88–92%)
- Minimize IV fluids to avoid volume overload
Suggested reading
- Groenewold MD, Olthof CG, Bosch DJ. Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy. BJA Educ. 2022;22(1):12-19.
- Brandt JP, Gerriets V. Bleomycin. [Updated 2022 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555895/
- Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacological Research. 2015;97:122-30.
- Allan N, Siller C, Breen A. Anaesthetic implications of chemotherapy. Continuing Education in Anaesthesia Critical Care & Pain. 2012;12(2):52-6.
Nerve Blocks App
Pain Medicine Assistant App
POCUS App
MSK Knee App
VetRA App
Nerve Block Manual
Regional Anesthesia Updates
Anesthesiology Manual
Anesthesiology Review
Anesthesia Updates 2025
Anesthesia Updates 2026
Pediatric Anesthesia Updates
Airway Management Updates
US Interventional Pain Manual
Pain Medicine Updates
Mastering Difficult IV Access
PACU Nursing Manual
RA Veterinary Manual